These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 8210642)

  • 61. 15-Deoxyspergualin produces inhibition of lymphokine-activated killer cell activity.
    Thomas F; Matthews C; Pittman K; Thomas J
    Transplant Proc; 1992 Apr; 24(2):712-3. PubMed ID: 1566494
    [No Abstract]   [Full Text] [Related]  

  • 62. Interleukin-2 in bone marrow transplantation: preclinical studies.
    Charak BS; Choudhary GD; Tefft M; Mazumder A
    Bone Marrow Transplant; 1992 Aug; 10(2):103-11. PubMed ID: 1326364
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Antitumor activity against established intracerebral gliomas exhibited by cytotoxic T lymphocytes, but not by lymphokine-activated killer cells.
    Holladay FP; Heitz T; Wood GW
    J Neurosurg; 1992 Nov; 77(5):757-62. PubMed ID: 1403119
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Swainsonine augments the cytotoxicity of human lymphokine-activated killer cells against autologous thyroid cancer cells.
    Fujieda S; Noda I; Saito H; Hoshino T; Yagita M
    Arch Otolaryngol Head Neck Surg; 1994 Apr; 120(4):389-94. PubMed ID: 8166967
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Cytolytic potential of peripheral blood T-lymphocytes following adoptive immunotherapy with lymphokine-activated killer cells and low-dose interleukin 2.
    Yoshino I; Yano T; Murata M; Ishida T; Sugimachi K; Kimura G; Nomoto K
    Cancer Res; 1991 Mar; 51(5):1494-8. PubMed ID: 1997188
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Generation of lymphokine-activated killer cells in long-term cultures.
    Hartwig M; Körner IJ
    Immunology; 1990 Sep; 71(1):145-7. PubMed ID: 2210801
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Phenotypical study of human lymphokine-activated killer (LAK) cells.
    Barral AM; García CA
    Neoplasma; 1989; 36(5):583-8. PubMed ID: 2682296
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Augmentation of antileukemia lytic activity by OKT3 monoclonal antibody: synergism of OKT3 and interleukin-2.
    Lotzová E; Savary CA; Herberman RB; McCredie KB; Keating MJ; Freireich EJ
    Nat Immun Cell Growth Regul; 1987; 6(5):219-23. PubMed ID: 3502169
    [TBL] [Abstract][Full Text] [Related]  

  • 69. An investigation of factors influencing the in vitro induction of LAK activity against a variety of human bladder cancer cell lines.
    Jackson AM; Hawkyard SJ; Prescott S; Ritchie AW; James K; Chisholm GD
    J Urol; 1992 Jan; 147(1):207-11. PubMed ID: 1729534
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [Augmentation of cytotoxic activity by combination with interleukin 2 and interferon gamma].
    Tsunoda T; Tanimura H; Yamaue H; Tani M; Iwahashi M
    Nihon Gan Chiryo Gakkai Shi; 1990 Jun; 25(6):1110-8. PubMed ID: 2118938
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Proliferation and cytotoxicity of lectin-induced lymphokine-activated killer (LILAK) cells.
    Shimizu Y; Kuroki T; Shiomi S; Kobayashi K; Monna T
    J Gastroenterol Hepatol; 1991; 6(5):485-90. PubMed ID: 1657242
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Human tumor cell line resistance to chemotherapeutic agents does not predict resistance to natural killer or lymphokine-activated killer cell-mediated cytolysis.
    Harker WG; Tom C; McGregor JR; Slade L; Samlowski WE
    Cancer Res; 1990 Sep; 50(18):5931-6. PubMed ID: 1975512
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Induction of lymphokine-activated killer cells of equine origin: specificity for equine target cells.
    Hormanski CE; Truax R; Pourciau SS; Folsom RW; Horohov DW
    Vet Immunol Immunopathol; 1992 Apr; 32(1-2):25-36. PubMed ID: 1604800
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Agar capillary clonogenic microassays for cellular immunocytotoxic activities in human leukaemia and lymphoma.
    Maurer HR; Hassan HT
    Leuk Lymphoma; 1993 Mar; 9(4-5):305-13. PubMed ID: 7688626
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Follicular lymphoma: in vitro effects of combining lymphokine-activated killer (LAK) cell-induced cytotoxicity and rituximab- and obinutuzumab-dependent cellular cytotoxicity (ADCC) activity.
    García-Muñoz R; López-Díaz-de-Cerio A; Feliu J; Panizo A; Giraldo P; Rodríguez-Calvillo M; Grande C; Pena E; Olave M; Panizo C; Inogés S
    Immunol Res; 2016 Apr; 64(2):548-57. PubMed ID: 26659089
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Interleukin-2 therapy after autologous bone marrow transplantation for hematologic malignancies.
    Fefer A; Benyunes MC; Massumoto C; Higuchi C; York A; Buckner CD; Thompson JA
    Semin Oncol; 1993 Dec; 20(6 Suppl 9):41-5. PubMed ID: 8284691
    [No Abstract]   [Full Text] [Related]  

  • 77. Analysis of interleukin 2 and various effector cell populations in adoptive immunotherapy of 9L rat gliosarcoma: allogeneic cytotoxic T lymphocytes prevent tumor take.
    Kruse CA; Lillehei KO; Mitchell DH; Kleinschmidt-DeMasters B; Bellgrau D
    Proc Natl Acad Sci U S A; 1990 Dec; 87(24):9577-81. PubMed ID: 2263613
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The interleukin (IL) 2 receptor beta chain is shared by IL-2 and a cytokine, provisionally designated IL-T, that stimulates T-cell proliferation and the induction of lymphokine-activated killer cells.
    Bamford RN; Grant AJ; Burton JD; Peters C; Kurys G; Goldman CK; Brennan J; Roessler E; Waldmann TA
    Proc Natl Acad Sci U S A; 1994 May; 91(11):4940-4. PubMed ID: 8197161
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Purging of malignant cells from blood after short ex vivo incubation with NK-92 cells.
    Klingemann HG; Miyagawa B
    Blood; 1996 Jun; 87(11):4913-4. PubMed ID: 8639869
    [No Abstract]   [Full Text] [Related]  

  • 80. Susceptibility of human leukemia cells to allogeneic and autologous lymphokine-activated killer cells and its augmentation by exposure of leukemia target cells to cytotoxic drugs in vitro and in vivo.
    Teichmann JV; Ludwig WD; Thiel E
    Recent Results Cancer Res; 1993; 131():223-38. PubMed ID: 8210642
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.